INTRODUCTION
============

The nuclear envelope (NE) is a subdomain of the endoplasmic reticulum (ER) that encloses the genome and delineates the nuclear compartment in eukaryotic cells ([@B18]). It is defined by concentric inner and outer nuclear membranes (INM and ONM, respectively) separated by an ∼30--50 nm perinuclear space (PNS) that is contiguous with the ER lumen ([@B42]). The INM contains a unique set of proteins that interact with the underlying nuclear lamina and chromatin, while the ONM is an extension of the ER ([@B2]). INM--ONM fusion generates fenestrations throughout the NE that are occupied by nuclear pore complexes ([@B43]).

Though most nuclear--cytoplasmic communication occurs via nuclear pore complexes ([@B19]), it can also be mechanical in nature, such that forces generated by the cytoskeleton are transmitted across the NE into the nucleoplasm by LINC complexes ([@B1]). These conserved NE-spanning molecular bridges are critical for cell division, DNA damage repair, meiotic chromosome pairing, mechanoregulation of gene expression, and nuclear positioning ([@B30]). Underscoring their importance is a growing list of genetic mutations in LINC complex proteins associated with human diseases including ataxia and muscular dystrophy ([@B13]).

LINC complexes are composed of the ONM *Klarsicht*/*ANC-1*/*SYNE* homology (KASH) proteins and the INM *Sad1*/*UNC-84* (SUN) proteins ([@B6]). KASH proteins are defined by a C-terminal KASH domain, which includes a transmembrane domain followed by the ∼10--32-residue luminal KASH peptide ([@B39]). The divergent N-termini of KASH proteins extend into the cytoplasm, where they engage the cytoskeleton and signaling molecules ([@B25]). SUN proteins are identified by their KASH-binding luminal C-terminal SUN domain ([@B29]), whereas their N-termini interact with A-type lamins, chromatin, and other INM proteins within the nucleoplasm ([@B3]).

Mammals encode two major SUN proteins, SUN1 and SUN2, which are widely expressed in somatic cells ([@B30]). Consistent with their high level of sequence similarity (e.g., mouse SUN1 and SUN2 share 65% identity), SUN1 and SUN2 perform redundant functions during the DNA damage response ([@B21]) and radial neuronal migration in the developing mouse cerebral cortex and hippocampus ([@B47]), as well as synaptic nuclear anchorage in mouse skeletal muscle ([@B20]). These redundancies may be due to the ability of both SUN1 and SUN2 to interact promiscuously with the KASH peptide of several KASH proteins including nesprin-1, -2, and -3 ([@B40]). Nevertheless, examples of SUN protein function specificity also exist. For example, SUN1 is differentially required for meiotic chromosome pairing ([@B7]; [@B14]) and nuclear pore complex insertion and distribution ([@B23]; [@B41]). However, the molecular mechanisms underlying the redundant and specific functions of SUN1 and SUN2 remain unclear.

Recent in vitro studies reveal that SUN2 trimerizes due to the presence of a coiled coil (CC)--containing helical region within its luminal domain ([@B31]; [@B38]; [@B44]). SUN2 oligomerization is essential for KASH binding, which is further stabilized by an intermolecular disulfide bond formed between conserved cysteine residues in the SUN domain and KASH peptide ([@B38]). Despite these important mechanistic advances, the in vivo relevance of SUN protein trimerization remains unclear due to the lack of suitable methods for measuring protein assembly states within the NE. Here, we sought to address this deficiency by extending the application of FFS ([@B35]) to quantify protein--protein interactions in the NE in living cells.

RESULTS AND DISCUSSION
======================

Quantifying NE protein--protein interactions in living cells
------------------------------------------------------------

FFS characterizes fluctuating fluorescence signals generated by fluorescently labeled proteins passing through the optical observation volume of a confocal or two-photon microscope ([@B35]). Subsequent brightness analysis of these fluorescence fluctuations provides quantitative information about the stoichiometry of the labeled proteins ([@B5]). We recently combined FFS with z-scans to quantify protein--protein interactions at the plasma membrane and in thin cell sections ([@B27]; [@B37]). Given the ∼30--50-nm thickness of the PNS, we explored the use of FFS and z-scans as a method of quantifying protein--protein interactions within the NE. For simplicity, we refer to the INM, ONM, and PNS collectively as the NE for the remainder of this work.

A z-scan consists of an axial scan of the two-photon spot through a cell expressing a fluorescently labeled protein ([Figure 1A](#F1){ref-type="fig"}; [@B27]). The resulting axial intensity profile or "z-scan" characterizes the subcellular distribution of the labeled proteins. Thus, a labeled NE protein produces a z-scan with two peaks along the trajectory, which correspond to signals generated within the ventral and dorsal NE. To quantify the fluorescence contributions from the NE and the nucleoplasm, z-scans were analyzed as previously described ([@B37], [@B36]). FFS data were collected with the two-photon spot repositioned at either NE.

![FFS and brightness analysis in the NE. (A) Identification of the dorsal (NE~D~) and ventral (NE~V~) NEs in a cell expressing EGFP-tagged NE proteins by z-scan FFS. Fluorescence intensity fluctuations are measured at either NE. (B) Constructs used in this figure. (C) Representative epifluorescence images of U2OS cells expressing the indicated constructs. Scale bar: 5 μm. (D) Brightness analysis of the cells described in C. Each data point represents the average *b* measured in a single cell.](mbc-29-1003-g001){#F1}

We initially tested the feasibility of FFS and brightness analysis within the NE by measuring the normalized brightness (*b*) of EGFP in this subcellular compartment. EGFP was targeted to the ER lumen/PNS by adding the signal sequence (SS) from a luminal protein, torsinA ([@B11]; [Figure 1B](#F1){ref-type="fig"}). The *b* indicates the average oligomeric state of an EGFP-tagged protein ([@B45]); that is, a monomer and a dimer correspond to a *b* of 1 and 2, respectively. To confirm that brightness accurately reflects stoichiometry within the NE, we measured the *b* of a dimeric EGFP construct (SS-EGFP~2~; [@B5]). Following expression, both constructs localized to the ER/NE ([Figure 1C](#F1){ref-type="fig"}). z-scans and FFS data for these constructs were collected from expressing cells, followed by the calculation of *b* and number concentration (*N*), which is the average number of EGFPs within the observation volume. Further details on *b* and *N* can be found in *Materials and Methods*.

Independent of *N*, the mean and standard deviation of *b* from SS-EGFP- or SS-EGFP~2~--expressing cells was 1.06 ± 0.14 and 1.98 ± 0.18, respectively ([Figure 1D](#F1){ref-type="fig"}). These results are, within experimental uncertainty, consistent with SS-EGFP being monomeric and SS-EGFP~2~ dimeric within the NE. This work establishes FFS and brightness analysis as a powerful method for probing the in vivo biochemical and biophysical behavior of NE proteins within their native cellular environment.

SUN2 oligomerization in the NE
------------------------------

Next, we sought to detect in vivo SUN2 trimerization using FFS and brightness analysis. Because quantitative brightness analysis of FFS data requires labeled proteins to be mobile ([@B15]) and full-length EGFP-tagged SUN2 was shown to be highly immobile by fluorescence recovery after photobleaching (FRAP; [@B32]), we generated and measured the oligomerization of a SS-EGFP-tagged construct that encodes the entire luminal domain of SUN2 (SS-EGFP-SUN2^261--731^) ([Figure 2A](#F2){ref-type="fig"}). We also generated SS-EGFP-SUN2^520--731^ and SS-EGFP-SUN2^595--731^, which encode a noncanonical CC through the SUN domain and the SUN domain alone, respectively ([Figure 2A](#F2){ref-type="fig"}). The absence of a transmembrane domain liberates these constructs from membrane-induced constraint, enabling diffusion throughout the ER lumen/PNS ([Figure 2B](#F2){ref-type="fig"}). Nevertheless, it should be noted that the transmembrane domain itself could influence SUN protein oligomerization. This possibility should be addressed in future studies.

![SUN2 oligomerization in the NE. (A) Constructs used in this figure. (B) Represent­ative epifluorescence images of U2OS cells expressing the indicated constructs. Scale bar: 5 μm. (C--E) Plots of *b* vs. *N* for the indicated constructs. The data in C were fitted to a monomer/dimer/trimer binding model (solid red line), which is shown in D and E (dashed red line), with *K*~MD~ = 4100 (1000 μM) , *K*~DT~ = 0.06 (0.01 μM) , and a monomer/trimer binding model (solid green line) with *K*~MT~ = 26 (6 μM) ± 7.](mbc-29-1003-g002){#F2}

Plotting *b* versus *N* revealed a concentration-dependent increase in *b* with values mainly between 2 and 3 for *N* \> 50 ([Figure 2C](#F2){ref-type="fig"}). These data show that SS-EGFP-SUN2^261--731^ exhibits an average oligomerization state that is between dimer and trimer. While the *b* binding curve has not yet achieved saturation within the experimentally accessible concentration range, the data are approaching the next integer *b* of 3, suggesting a limiting trimeric stoichiometry as supported by fitting the data to a monomer/dimer/trimer binding model ([Figure 2C](#F2){ref-type="fig"}). The fitted monomer/dimer (*K*~MD~ = 4100) and dimer/trimer (*K*~DT~ = 0.06) dissociation coefficients, in units of *N* for the monomer/dimer and dimer/trimer reaction, indicate that dimers are a minority species, since *K*~MD~ \> *K*~DT.~ Thus, the *b* binding curve can also be modeled by a monomer/trimer equilibrium ([Figure 2C](#F2){ref-type="fig"}). Molar values for the dissociation coefficients were estimated as described in *Materials and Methods* and are quoted in the figure caption.

The *b* of SS-EGFP-SUN2^520--731^ increased with *N* and approached 3 at high *N* ([Figure 2D](#F2){ref-type="fig"}). While these data are on the average slightly below the binding curve for *N* \< 100, the differences are small. Unlike either SS-EGFP-SUN2^261--731^ or SS-EGFP-SUN2^520--731^, the *b* values obtained for SS-EGFP-SUN2^595--731^ remain close to one and do not increase with concentration ([Figure 2E](#F2){ref-type="fig"}). These results demonstrate SUN2 trimerization within the NE of living cells and that the SUN domain is not sufficient for this oligomerization, consistent with previously reported in vitro studies ([@B38]; [@B44]).

While SUN2^261--731^ contains both types of CC, SUN2^520--731^ possesses only the noncanonical CC. Despite this difference, both constructs displayed similar *N*-dependent oligomerization within the NE ([Figure 2, C and D](#F2){ref-type="fig"}) suggesting that the noncanonical CC may be sufficient for SUN2 trimerization, in agreement with the use of a similar human SUN2 construct to solve the crystal structure of SUN2 trimers ([@B38]).

SUN1 oligomerization in the NE
------------------------------

To provide insight into the conservation of SUN protein trimerization, we next investigated the oligomerization of SUN1 within the NE. Like SUN2, EGFP-tagged full-length SUN1 was shown by FRAP to be immobile ([@B32]). Consequently, we generated an SS-EGFP-tagged construct encoding the entire luminal domain of SUN1 (SS-EGFP-SUN1^457--931^) ([Figure 3A](#F3){ref-type="fig"}). Owing to the lack of structural information available for SUN1, we limited our analysis to this construct, which was analogous to SS-EGFP-SUN2^520--731^ (SS-EGFP-SUN1^702--913^), and another that encodes the SUN1 SUN domain (SS-EGFP-SUN1^777--913^; [Figure 3A](#F3){ref-type="fig"}). All three constructs localized to the peripheral ER and NE ([Figure 3B](#F3){ref-type="fig"}).

![SUN1 oligomerization in the NE. (A) Constructs used in this figure. (B) Represen­tative epifluorescence images of U2OS cells expressing the indicated constructs. Scale bar: 5 μm. (C--E) Plots of *b* vs. *N* for the indicated constructs. The data in C were fitted to a linear regression (solid red line), which is shown in D and E (dashed red line).](mbc-29-1003-g003){#F3}

The *b* of SS-EGFP-SUN1^457--913^ increased linearly over the entire range of *N* ([Figure 3C](#F3){ref-type="fig"}), which prohibited the fitting of the data to a binding curve and the estimation of the stoichiometry of this construct. Nevertheless, the highest *b* value measured for SS-EGFP-SUN1^457--913^ was ∼5, indicating the presence of higher-order oligomeric states than those observed for SS-EGFP-SUN2^261--731^. In contrast to what was observed for SS-EGFP-SUN2^520--731^, the *b* of SS-EGFP-SUN1^702--913^ did not increase appreciably above 1 over the range of measured *N* ([Figure 3D](#F3){ref-type="fig"}). Finally, a lack of oligomerization similar to what was observed for SS-EGFP-SUN2^595--731^, was also reflected by the *b* values obtained for the SUN domain encoding the SS-EGFP-SUN1^777--913^ construct ([Figure 3E](#F3){ref-type="fig"}). These results suggest that trimers are not the limiting assembly state for all SUN proteins, which is in agreement with a previous report of the existence of immobile macromolecular assemblies of SUN1 within the NE composed of dimers and tetramers ([@B23]).

SUN protein oligomerization in the cytoplasm
--------------------------------------------

Given the requirement of SUN2 trimerization for KASH-binding ([@B38]), SUN protein oligomerization may represent an important target for the regulation of LINC complex assembly. In fact, a recent report shows that the two canonical CCs of SUN2 display distinct oligomeric states, the modulation of which regulates the ability of SUN2 to interact with KASH peptides ([@B31]). However, the mechanisms responsible for regulating SUN2 oligomerization within the NE remain unknown. As an initial step toward defining these mechanisms, we quantified the oligomerization of constructs encoding EGFP-tagged luminal domains of SUN1 or SUN2 in the heterologous subcellular environment of the cytoplasm.

Cytoplasmic expression of these constructs was achieved by removing the SS ([Figure 4, A and B](#F4){ref-type="fig"}). FFS experiments were performed in the cytoplasm of these cells as previously described ([@B27], [@B26]). The *b* of EGFP-SUN2^261--731^ increased with *N* and appeared to reach a limiting value of 3 at *N* \> 600 ([Figure 4C](#F4){ref-type="fig"}), which agrees with the estimated stoichiometry of the analogous construct in the NE. A fit of the cytosolic *b* data measured for cytoplasmic EGFP-SUN2^261--731^ to a monomer/dimer/trimer binding curve is shown with *K*~MD~ = 8000 and *K*~DT~ = 0.3 ([Figure 4C](#F4){ref-type="fig"}). Because *K*~DT~ \> *K*~MD~, the dimer population is negligible and a monomer/trimer equilibrium is sufficient to describe the *b* binding curve for EGFP-SUN2^261--731^ (Supplemental Figure S1A).

![SUN1 and SUN2 oligomerization in the cytoplasm. (A) Constructs used in this figure. (B) Representative epifluorescence images of U2OS cells expressing the indicated constructs. Scale bar: 5 μm. (C--G) Plots of *b* vs. *N* for the indicated constructs. The data in C were fitted to a trimeric binding model (solid blue line), which is shown in D and E (dashed blue line) with *K*~MD~ = 8000 (60 μM) ± 4000 and *K*~DT~ = 0.3 (0.002 μM) ± 0.2. The data in F were fitted to a monomer/trimer/hexamer binding model (solid blue line) with *K*~MT~ = 100 (0.7 μM) ± 60 and a trimer--hexamer dissociation coefficient *K*~TH~ = 1500 (10 μM) ± 400, which is then shown in G (dashed blue line). Estimated binding curves (dashed red lines) for the data obtained in the NE for the indicated constructs are presented in C and F by converting *N* from the NE to its cytoplasmic value.](mbc-29-1003-g004){#F4}

Only the cytoplasmic observation volume is experimentally obtainable ([@B26]). Thus, we computed an estimated NE observation volume to express *N* values in the NE as an approximate equivalent cytoplasmic *N* by accounting for the volume difference (see *Materials and Methods*). Applying this procedure converts the trimeric NE *b* binding curve ([Figure 2C](#F2){ref-type="fig"}) to a predicted *b* binding curve in the cytoplasm ([Figure 4C](#F4){ref-type="fig"}). A comparison of the trimeric NE binding curve and the predicted cytoplasmic binding curve demonstrates that the observed *b* increase with *N* in the cytoplasm is significantly more pronounced than was observed in the NE (see figure legends for more details). In contrast, both EGFP-SUN2^520--731^ and EGFP-SUN2^595--731^ appeared to be monomeric, as their *b* values remained near 1 ([Figure 4, E and F](#F4){ref-type="fig"}). These results reveal that the oligomerization of EGFP-tagged SUN2^261--731^ and SUN2^520--731^ is sensitive to as yet unidentified environmental factors.

In addition, differences in the behavior of the SUN1^457--913^ constructs in the cytoplasm relative to the NE were also observed. While the *b* of SS-EGFP-SUN1^457--913^ and EGFP-SUN1^457--913^ rises with increasing *N*, the *b* increase of EGFP-SUN1^457--913^ within the cytoplasm slows at higher concentrations, unlike the linear increase with *N* we observed in the NE ([Figure 4F](#F4){ref-type="fig"}; see figure legend for more details). However, the *b* of EGFP-tagged SUN1^457--913^ rises much faster in the cytoplasm than on the predicted *b* curve, which was converted from the NE *b* binding reaction ([Figure 3C](#F3){ref-type="fig"}).

Unlike EGFP-SUN2^261--731^, EGFP-SUN1^457--913^ does not reach the same *b* levels in the cytoplasm as in the NE. Instead, the *b* data slightly exceed 3 in the cytoplasm at high *N* values. A fit of the *b* values to a monomer/dimer/trimer binding model reveals that the tail of the binding curve (*N* \> 500) is not reproduced by the model (Supplemental Figure S1B). This misfit implies the need for at least one stoichiometric state in excess of a trimer for EGFP-SUN1^457--913^ in the cytoplasm. While a monomer/trimer/hexamer binding model was sufficient to describe the experimental data, a monomer/dimer/tetramer binding model could also reproduce the data (Supplemental Figure S1C), consistent with a previous report of the existence of SUN1 dimers and tetramers ([@B23]). Currently, our data cannot distinguish between these different binding models. Finally, the *b* of EGFP-SUN1^777--913^ remains close to 1 over the measured concentration range ([Figure 4G](#F4){ref-type="fig"}), in agreement with the behavior observed for SS-EGFP-SUN1^777--913^ in the NE. Because it did not display appreciable oligomerization within the NE, we did not measure the oligomerization of EGFP-tagged SUN1^702--913^ in the cytoplasm.

A more pronounced *N*-dependent *b* increase for EGFP-tagged SUN2^261--731^ and SUN1^457--913^ was observed in the cytoplasm than in the NE ([Figure 4, C and F](#F4){ref-type="fig"}). A potential explanation for these results could be the presence of unlabeled endogenous SUN proteins within the NE that compete with these labeled SUN constructs, leading to a reduction in *b*. This competition leads to an apparent reduction in the measured binding affinity ([@B4]), which potentially explains the shift of the binding curve of EGFP-tagged SUN2^261--731^ and SUN1^457--913^ to lower *N*. Unlike the binding affinity, the saturating value of *b* remains unchanged and is approached after the exogenously expressed EGFP-tagged protein concentration exceeds the endogenous concentration as well as the *K*~D~ value, thereby identifying the stoichiometry of EGFP-tagged protein complexes ([@B4]).

To directly verify that the reported brightness values for the SS-EGFP-tagged luminal domains of SUN1 and SUN2 ([Figures 2C](#F2){ref-type="fig"} and [3C](#F3){ref-type="fig"}) are not lowered by the endogenous population, we performed additional measurements of both SS-EGFP-SUN2^261--731^ and SS-EGFP-SUN1^457--913^ in U2OS cells expressing a short hairpin RNA (shRNA), which efficiently depleted either endogenous SUN1 or SUN2, or a noncoding (NC) control shRNA (Supplemental Figure S2A). SS-EGFP-SUN2^261--731^ was previously observed to approach the saturating value *b* = 3 for values of 100 *\< N* \< 200 ([Figure 2C](#F2){ref-type="fig"}). Therefore, we selected SUN2 shRNA-expressing cells with concentrations of SS-EGFP-SUN2^261--731^ in this range, measured *b*, and then calculated the median and quartile values (Supplemental Figure S2B). Comparing *b* in the absence of shRNA with *b* in the presence of either NC or SUN2 shRNA resulted in *p* values of 0.88 and 0.85, respectively. These results suggest that the *b* measured for SS-EGFP-SUN2^261--731^ is unaffected by the absence or presence of endogenous SUN2, and thus the reported *b* values accurately reflect the average stoichiometry of SS-EGFP-SUN2^261--731^ at concentrations of 100 *\< N* \< 200.

Similarly, we compared *b* measurements in the presence and absence of NC or SUN1-depleting shRNA (Supplemental Figure S3A) over the range 100 *\< N* \< 200. As with SS-EGFP-SUN2^261--731^, we measured *b* and determined the median and quartiles. The *b* measurements performed on SS-EGFP-SUN1^457--913^ in the presence of NC or SUN1 shRNA resulted in *p* values of 0.78 and 0.61, respectively, indicating that the measured brightness is unaffected by the absence or presence of endogenous SUN1 (Supplemental Figure S3B). Taken together with our observations of SS-EGFP-SUN2^261--731^, these results demonstrate that the presence of endogenously expressed unlabeled SUN proteins has a negligible impact on our reported brightness at the higher concentrations we measured. Furthermore, the loss of SUN2^520--731^ oligomerization in the cytoplasmic environment as compared with the NE ([Figures 2D](#F2){ref-type="fig"} and [4D](#F4){ref-type="fig"}) cannot be caused by endogenous competition in the NE, since such competition can only lower the brightness in the NE environment.

Thus, our data imply the existence of unidentified regulators of SUN protein oligomerization within the NE, which may be chemical in nature. For instance, the contiguous ER lumen and PNS have a high calcium concentration and an oxidizing environment that favors the formation of disulfide bonds ([@B9]). Because the conserved cation loop in the SUN domain of SUN2 is required for KASH binding, which also requires SUN2 trimerization ([@B38]), we anticipate that SUN protein oligomerization may be sensitive to changes in the concentration of calcium within the PNS. In addition, SUN1 oligomerization involves interchain disulfide bonds, which leads us to speculate that SUN protein oligomerization may be influenced by the redox potential of the ER lumen/PNS ([@B9]). Alternatively, luminal proteins such as the AAA+ ATPase torsinA, which was recently shown to localize to and be required for the assembly of transmembrane actin-associated (TAN) lines in migrating fibroblasts ([@B34]), may structurally regulate SUN protein oligomerization.

Models of SUN1 and SUN2 oligomerization
---------------------------------------

We propose that SUN2 monomers are in equilibrium with SUN2 trimers in the NE, with no evidence for a significantly populated dimeric state ([Figure 5A](#F5){ref-type="fig"}). Currently, we cannot distinguish between two models of SUN1 oligomerization that are not mutually exclusive ([Figure 5](#F5){ref-type="fig"}, B' and B"). In the first, SUN1 oligomerizes via a monomer/dimer/tetramer reaction ([Figure 5B](#F5){ref-type="fig"}'). In the second, SUN1 oligomerizes via a monomer/trimer/hexamer reaction ([Figure 5B](#F5){ref-type="fig"}"). Both reactions would ultimately lead to the assembly of higher-order SUN1 oligomers through progressive oligomerization (i.e., monomer to trimer to hexamer to *n*-mer). The second model is favored based on recently published computational modeling results from the Mofrad laboratory, which suggest that, like SUN2, SUN1 is capable of forming stable homo-trimers ([@B17]). However, they found that unlike SUN2 homo-trimers, SUN1 homo-trimers were able to form lateral complexes via the association of their SUN domains. This model is consistent with our observation of *b* values in excess of trimers for the case of SS-EGFP-SUN1^457--913^. Future work will be needed to carefully explore the modeling predictions put forward by the Mofrad laboratory.

![Models of SUN1 and SUN2 oligomerization. (A) Working model of SUN2 oligomerization. (B' and B'') Working models of SUN1 oligomerization with the NE, which lead to the assembly of higher-order SUN1 oligomers (SUN1~N~).](mbc-29-1003-g005){#F5}

The ability of SUN1 to form higher-order oligomers than SUN2 may be related to its ability to form rings around NE-associated meiotic telomeres ([@B14]) and to localize to nuclear pore complexes ([@B22]). These SUN1-specific localizations may explain the differential requirement for SUN1 during meiotic chromosome pairing and DNA double-stranded break repair ([@B7]; [@B14]; [@B46]) as well as nuclear pore complex insertion and distribution ([@B23], [@B41]). Moreover, SUN2 trimerization may be required for actin-dependent nuclear movement, as demonstrated by the specific recruitment of SUN2 to TAN lines in migrating fibroblasts ([@B24]). Future efforts aimed at further understanding the mechanisms of the differential oligomerization of SUN1 and SUN2 will provide important insights into LINC complex-­dependent mechanotransduction and nuclear--cytoplasmic communication.

MATERIALS AND METHODS
=====================

Antibodies
----------

Anti-EGFP mouse monoclonal antibody (mAb) MAB3580 was purchased from Sigma-Aldrich and was used at a dilution of 1:200 for immunofluorescence. Anti-SUN1 (ab74758) and -SUN2 (ab87036) were used at a 1:200 dilution to validate the shRNA-mediated depletion of SUN1 or SUN2 by immunofluorescence. Secondary antibodies were from two different sources. From Jackson ImmunoResearch Laboratories, we purchased goat anti-mouse secondary antibodies conjugated to Alexa Fluor 488 or rhodamine. From ThermoFisher Scientific, we purchased goat anti-rabbit secondary antibodies conjugated to Dylight 488 or 561. All secondary antibodies were used at a 1:200 dilution for immunofluorescence.

Reagents
--------

4′,6-Diamidino-2-phenylindole (DAPI) was purchased from ThermoFisher Scientific. Restriction enzymes were either purchased from New England Biolabs (NEB) or Promega. Phusion DNA polymerase, T4 DNA ligase, and T4 PolyNucleotide Kinase (PNK) were also purchased from NEB. All other chemicals were from Sigma-Aldrich unless otherwise specified. Wizard SV Gel and the PCR Clean-Up System were from Promega. The GeneJet Plasmid Midiprep Kit was from ThermoFisher Scientific.

Cell culture
------------

U2OS cells obtained from the American Type Culture collection were cultured using standard sterile technique in DMEM with 10% fetal bovine serum (FBS) from Hyclone Laboratories.

DNA constructs
--------------

NC (TR30015), SUN1 (TF300647B/FI302582), and SUN2 (TF300646A/FI302577) HuSH-29 shRNA constructs in pRFP-C-RS were purchased from OriGene Technologies). The SS-EGFP and SS-EGFP~2~ constructs were generated as follows, using a previously described human SS-EGFP-torsinA construct ([@B11]). EGFP from SS-EGFP-torsinA was PCR-amplified using the primers SS-EGFP-F and SS-EGFP-R ([Table 1](#T1){ref-type="table"}), which contain 5' *Nhe*I and *Eco*RI cut sites, respectively. The PCR product was purified and digested alongside SS-EGFP-torsinA with *Nhe*I and *Eco*RI. Following gel purification, the digested PCR product and plasmid were ligated together to create SS-EGFP. To generate SS-EGFP~2~, EGFP was amplified from SS-EGFP-torsinA using the primers SS-EGFP~2~-F and SS-EGFP~2~-R ([Table 1](#T1){ref-type="table"}), which contain 5' *Bsr*GI and *Apa*I cut sites, respectively. In addition, SS-EGFP~2~-F encodes a 10--amino acid linker (GHGTGSTGSG) following the *Bsr*GI site, while SS-EGFP2-R encodes a mutated *Bsr*GI site that disrupts the 3' *Bsr*GI present in EGFP. The resulting PCR product was then purified and digested beside SS-EGFP with *Bsr*GI and *Apa*I. The digested PCR product and plasmid were purified and ligated to make SS-EGFP~2~.

###### 

Primers used to generate the constructs used in this paper.

  Primer name                DNA sequence                                                             5' RE site
  -------------------------- ------------------------------------------------------------------------ ------------
  SS-EGFP-F                  GTG[GCTAGC]{.ul}GTGAGCAAGGGCGAGGAG                                       *Nhe*I
  SS-EGFP-R                  GACTGACT[GAATTC]{.ul}CTACTTGTACAGCTCGTCCATG                              *Eco*RI
  SS-EGFP~2~-F               GC[TGTACA]{.ul}AG**GGGCACGGGACCGGGTCTACAGGGAGCGGG**AGCGTGAGCAAGGGCGAGG   *Bsr*GI
  SS-EGFP~2~-R               **AAC[GGGCCC]{.ul}GGCTGCCAATCATGACTG**TTACTTATACAGCTCGTCCATGCCG          *Apa*I
  SS-EGFP-SUN1^457--913^-F   GC[TGTACA]{.ul}AG**GGGCACGGGACCGGGTCTACAGGGAGCGGG**AGGGTGGACGATTCCAAGG   *Bsr*GI
  SS-EGFP-SUN1^457--913^-R   [GAATTC]{.ul}CTACTGGATGGGCTCTCCG                                         *Eco*RI
  SS-EGFP-SUN1^702--913^-F   ACATCCGAGGCTATTGTGTC                                                     ---
  SS-EGFP-SUN1^777--913^-F   TGGTACTTCTCACAGTCACC                                                     ---
  SS-EGFP-SUN2^261--731^-F   GC[TGTACA]{.ul}AG**GGGCACGGGACCGGGTCTACAGGGAGCGGG**TCCTGGTGGGCAGCAAAAG   *Bsr*GI
  SS-EGFP-SUN2^261--731^-R   TTTT[GAATTC]{.ul}CTAGTGGGCAGGCTCTC                                       *Eco*RI
  SS-EGFP-SUN2^520--731^-F   TTGGTGAGCCGCCGC                                                          ---
  SS-EGFP-SUN2^595--731^-F   TGGTACCACTCCCAGTCAC                                                      ---
  SS-EGFP-SUN^Δ^-R           CCCGCTCCCTGTAGACC                                                        ---
  SS^Δ^-F                    GTGGCTAGCGTGAGCAAGGG                                                     ---
  SS^Δ^-R                    CATGGATCCGAGCTCGGTACC                                                    ---

The F or R in the primer name refers to forward or reverse, respectively. Restriction enzyme (RE) cut sites are underlined. The sequence encoding the linker is bolded.

Previously described EGFP-tagged full-length mouse SUN1 and SUN2 constructs ([@B24]) were used as templates for the generation of the SS-EGFP-tagged luminal SUN1 and SUN2 constructs. To create SS-EGFP-SUN2^261--731^, the sequence encoding amino acids 261--731 was PCR amplified from EGFP-SUN2 using the SS-EGFP-SUN2^261--731^-F and SS-EGFP-SUN2^261---731^-R primer pair ([Table 1](#T1){ref-type="table"}), which contain 5' *Bsr*GI and *Eco*RI cut sites, respectively. In addition, SS-EGFP-SUN2^261--731^-F encodes a 10--amino acid linker (GHGTGSTGSG) following the *Bsr*GI site. The PCR product was purified and digested alongside SS-EGFP with *Bsr*GI and *Eco*RI. Following gel purification, the digested PCR product and plasmid were ligated together to create SS-EGFP-SUN2^261--731^. SS-EGFP-SUN2^520--731^ and SS-EGFP-SUN2^595--731^ were both generated via kinase, ligase, *Dpn*I treatment where 2 µl PCR product was treated with T4 ligase, T4 PNK, and *Dpn*I in T4 ligase buffer in a 20-µL reaction for 20 min at room temperature. The forward primers used to create SS-EGFP-SUN2^520--731^ and SS-EGFP-SUN2^595--731^ were SS-EGFP-SUN2^520--731^-F and SS-EGFP-SUN2^595--731^-F, respectively ([Table 1](#T1){ref-type="table"}). The same reverse primer, SS-EGFP-SUN2^Δ^-R ([Table 1](#T1){ref-type="table"}), was used for both SS-EGFP-SUN2^520--731^ and SS-EGFP-SUN2^595--731^.

To create SS-EGFP-SUN1^457--913^, the sequence encoding amino acids 457--913 was PCR-amplified from EGFP-SUN1 using the primers SS-EGFP-SUN1^457--913^-F and SS-EGFP-SUN2^457--913^-R ([Table 1](#T1){ref-type="table"}), which contain 5' *Bsr*GI and *Eco*RI cut sites, respectively. SS-EGFP-SUN1^457--913^-F also encodes a 10--amino acid linker (GHGTGSTGSG) following the *Bsr*GI site. The PCR product was purified and digested beside SS-EGFP with *Bsr*GI and *Eco*RI. Following gel purification, the digested PCR product and plasmid were ligated together to create SS-EGFP-SUN1^457--913^. SS-EGFP-SUN1^702--913^ and SS-EGFP-SUN1^777--913^ were generated via the kinase, ligase, *Dpn*I method as described above. The forward primers used to create SS-EGFP-SUN1^702--913^ and SS-EGFP-SUN1^777--913^ were SS-EGFP-SUN1^702--931^-F and SS-EGFP-SUN2^777--913^-F, respectively ([Table 1](#T1){ref-type="table"}). The same reverse primer, SS-EGFP-SUN^Δ^-R ([Table 1](#T1){ref-type="table"}), was used for both SS-EGFP-SUN1^702--913^ and SS-EGFP-SUN1^777--913^.

The cytoplasmic EGFP-tagged SUN1 and SUN2 constructs were generated via kinase, ligase, *Dpn*I reactions as follows. EGFP-SUN2^260--731^ and EGFP-SUN1^457--913^ were made first using the primers SS^Δ^-F and SS^Δ^-R ([Table 1](#T1){ref-type="table"}). Kinase, ligase, *Dpn*I treatments were used to make EGFP-SUN2^520--731^ and EGFP-SUN2^595--731^. The forward primers used to create EGFP-SUN2^520--731^ and EGFP-SUN2^595--731^ from EGFP-SUN2^260--731^ were SS-EGFP-SUN2^520--731^-F and SS-EGFP-SUN2^595--731^-F, respectively ([Table 1](#T1){ref-type="table"}). The same reverse primer, SS-EGFP-SUN2^deletion^-R ([Table 1](#T1){ref-type="table"}), was used for both EGFP-SUN2^520--731^ and EGFP-SUN2^595--731^. EGFP-SUN1^777--913^ was generated via kinase, ligase, *Dpn*I treatment from EGFP-SUN1^457--913^ using the primers SS-EGFP-SUN1^777--913^-F and SS-EGFP-SUN1^777--913^-R ([Table 1](#T1){ref-type="table"}).

Transfections
-------------

Transient transfections of cDNA and shRNA constructs were performed using GenJet from SignaGen Laboratories or Lipofectamine LTX from Invitrogen according to the manufacturers' instructions. Measurements were performed 24 or 48 h after transfection for FFS experiments in the absence or presence of shRNA, respectively. Immediately before measurement, the growth medium was replaced with Dulbecco's phosphate-buffered saline (PBS) with calcium and magnesium from Biowhittaker. Brightness measurements in the presence of shRNA were only performed on cells expressing turboRFP.

Fixed- and live-cell epifluorescence microscopy
-----------------------------------------------

All fixed-cell imaging was performed on an Eclipse Ni-E microscope driven by NIS-Elements software using a 40×/1.30 NA Plan Fluor oil immersion objective lens (Nikon Instruments, Melville, NY), a SOLA solid state white-light excitation subsystem (Lumencor), and a CoolSNAP ES2 CCD camera (Photometrics). A custom DAPI filter set (\#49028 with exciter: ET395/25x, dichroic: T425LPXR, and emitter: ET460/50m; Chroma Technology) was used for the SOLA light source. EGFP (C-FL EGFP Zero Shift, \#96362, Nikon Instruments), and Texas Red (C-FL Texas Red Zero Shift, \#96365; Nikon Instruments) filter sets were also used.

Twelve hours prior to their transfection, U2OS cells were grown in 24-well plates with \#1.5 glass coverslip bottoms or 35 mm dishes with \#1.5 glass coverslip bottoms from In Vitro Scientific. Cells were then washed twice with live imaging media composed of HBSS (GIBCO, Invitrogen) containing essential and nonessential MEM amino acids (Invitrogen), 2.5 g/l glucose, 2 mM glutamine, 1 mM sodium pyruvate, and 20 mM HEPES (pH 7.4) and transferred to a 37°C Okolab full-enclosure incubator (Ottaviano, Italy) with temperature control attached to a Intelligent Imaging Innovations (3I) Marianas 200 Microscopy Workstation built on a Zeiss AxioObserver Z.1 stand (Jena, Germany) and driven by SlideBook 6.0 from 3I. All live cell epifluorescence images were acquired with a Zeiss Plan-Apochromat 63x/1.4NA oil objective, a Sutter DG4 light source, and a Photometrics CoolSnap HQ2 CCD. A BrightLine Sedat filter set optimized for DAPI, FITC, TRITC, and CY5 from Semrock was used.

FFS measurements
----------------

The instrumental setup has been described previously ([@B16]). When measurements were performed in the presence of shRNA, a dichroic mirror with a center wavelength of 515 nm (515DCLPXR; Chroma Technology) was used to split the emission light of EGFP and turboRFP into "green" and "red" detection channels, and an additional short-pass filter centered at 512 nm (FF01-512/SP; Semrock) was added to the green channel to remove any reflected light from turboRFP. All analysis steps were performed with programs written in Research Systems IDL 8.3. The experimental two-photon spot or point-spread function (PSF) of the two-photon microscope was described using a modified squared Gaussian--­Lorentzian (mGL) model ([@B27], [@B26]). A z-scan calibration procedure was performed as previously described to determine the radial and axial beam waists (*w*~0~ and *z*~0~) and the axial decay parameter (*y*) ([@B27]), which resulted in *z*~0~ = 1.02 ± 0.1 µm, *y* = 2.30 ± 0.3, and *w*~0~ = 0.45 ± 0.05 μm. An initial z-scan passing through the nucleus of the cell generated a z-scan fluorescence intensity profile that was fitted using a previously described model ([@B37], [@B36]) to identify the fluorescence contributions from the ventral and dorsal NEs as well as the nucleoplasm. Cells with an intensity fraction of \>90% of fluorescence from the dorsal and ventral NEs were selected for further FFS measurements to ensure that the influence of fluorescence from non-NE sources on the analysis is negligible ([@B37]). An FFS measurement was conducted for 60 s and a sampling time *T* of 50 μs with the PSF centered on the ventral or dorsal NE. The collected photon counts were analyzed to extract Mandel's *Q* factor, , which is a measure of the variance of the fluorescence signal with respect to the mean ([@B33]; [@B16]; [@B12]). *Q* and the brightness λ, which is the photon count rate of a single molecule, are proportional to one another, *Q* = γ~2~λ*T* ([@B33]). The gamma factor γ~2~ depends on the PSF and the sample geometry ([@B37]). Given that the NE is significantly thinner (∼30--50 nm; [@B10]) than the two-photon spot produced by our microscope (∼1 μm), the NE acts as an infinitely thin "delta (δ)-layer" ([@B27]). For an mGL PSF centered on a δ-layer, γ~2~ is 0.5 ([@B27]). Additional FFS experiments performed in the nuclei of cells expressing EGFP serve to establish the raw brightness γ~*EGEP*~ as previously described ([@B5]). The normalized brightness *b* is defined by *b* = γ/γ~*EGEP*~, a dimensionless number that describes the average oligomeric state of the labeled protein ([@B26], [@B28]). For example, a homodimeric complex leads to *b* = 2. Brightness analysis for FFS experiments in the cytoplasm are performed as described above, but with an adjusted γ~2~ to reflect the different geometry. The value of γ~2~ has been determined using a z-scan FFS as described earlier ([@B27]).

The number concentration *N* represents the average number of labeled protein monomers in the observation volume. Because the brightness of an individual EGFP protein is given by γ~EGEP~, the time-averaged fluorescence intensity of a measurement is proportional to the number concentration, . We experimentally calculate *N* by dividing the average intensity by γ~EGEP~ ([@B5]). This procedure is valid for FFS experiments in the cytoplasm as well as at the NE. The observation volume *V*~*O*~ is given by the overlap between the two-photon PSF and the fluorescent sample. Converting the number concentration into a molar concentration is achieved by , where *N*~*A*~ is Avogadro's number. The volume of a cytoplasmic FFS experiment is measured using a previously published procedure ([@B27]). In contrast, the volume , and therefore the labeled protein concentration of FFS experiments at the NE, cannot be determined experimentally. However, molar concentrations in the NE can be estimated as described below.

Brightness modeling
-------------------

A monomer/dimer/trimer equilibrium reaction was used to model *b* as a function of *N*. The numbers of molecules of monomers, dimers, and trimers (*N*~1~, *N*~2~, *N*~3~) were determined by the reactions and with the dissociation coefficients *K*~MD~ and *K*~DT~, respectively. By definition, the normalized brightness of an *n*-mer is given by *b* = *n*. The brightness of this mixture of species is The total number of monomeric proteins in the observation volume is *A*~0~ = *A* + 2*A*~2~ + 3*A*~3~. The same analysis was performed for other binding equilibrium models, such as the monomer/trimer reaction with a dissociation coefficient defined by . A detailed description of the modeling is found in the Supplemental Materials. Fitting of the experimental data to *b* binding models was accomplished using bootstrapping ([@B8]). Confidence intervals of the estimated parameters were also determined from the bootstrap algorithm.

The observation volume of NE measurements is small compared to the observation volume of cytoplasmic FFS experiments, which is reflected in the measured *N*. To facilitate the comparison of *b* changes with concentration of a protein in both compartments, it is useful to translate between the measured *N* in both environments. This is achieved by the molar concentration, defined by , which demonstrates that the values of *N* in the cytoplasm and the NE are proportional to one another, . While the observation volume at the NE cannot be measured, it can be modeled as the product of the cross-sectional area of the PSF and the thickness *h* of the NE layer Given previously published measurements of NE thickness ([@B10]), we assume that the NE has an average thickness of *h* = 40 nm, which leads to a volume of 6.9 × 10^--3^ fl. This value is 34-fold smaller than the observation volume in the cytoplasm. Thus, the multiplication of *N* in the NE by 34 compensates for the difference in observation volume and determines the equivalent cytoplasmic *N*. The observation volume in the cytoplasm with a fully embedded PSF was determined to be 0.23 fl. These values served to calculate molar dissociation coefficients, which are quoted to one significant digit to reflect the uncertainties of the estimate.

Immunofluorescence
------------------

Cells grown on \#1.5 coverslips were fixed in --20°C methanol as previously described ([@B34]). Coverslips were mounted on slides using Fluoromount purchased from ThermoFisher Scientific.

Supplementary Material
======================

###### 

Click here for additional data file.
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CC

:   coiled coil

DAPI

:   4′,6-diamidino-2-phenylindole

INM

:   inner nuclear membrane

KASH

:   *Klarsicht, ANC-1*, SYNE homology

LINC

:   linker of nucleoskeleton and cytoskeleton

NE

:   nuclear envelope

ONM

:   outer nuclear membrane

PNS

:   perinuclear space

shRNA

:   short hairpin RNA

SUN

:   Sad1/*UNC-84*

TAN

:   transmembrane actin-­associated nuclear.
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